Hypertension
Conditions
Interventions
Normal dosage of telmisartan is administered for 6 months after randomization
Normal dosage of valsartan is administered for 6 months after randomization
Normal dosage of candesartan is administered f
Sponsors
3M STUDY GROUP
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with obesity whose BMI exceeding 25 2. Patients with hypertension (Systolic blood pressure is >=140 or diastolic >=90)
Exclusion criteria
Exclusion criteria: -patients with secondary hypertension -patients whose AST or ALT exceeding 100IU/L -patients with bile stenosis -patients with severe renal failure or nephrotic syndrome -patients with severe cerebral infarction -pregnant women or those who plan pregnancy, or in the lactation period -patients with neoplasm -patients with history of hypersensitivity to telmisartan, valsartan, or candesartan -other patients judged unsuitable for the study by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in fasting plasma glucose and insulin levels Change in serum lipid profile Change in high-sensitive CRP | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in serum adiponectin level Change in serum AGE-2 | — |
Countries
Japan
Contacts
Public ContactMasanari Mizuta
Department of Internal Medicine, University of Miyazaki Faculty of Medicine Neurology, Respirology, Endocrinology and Metabolism
Outcome results
None listed